AstraZeneca.
67 announcements.
67 announcements.
| Time | Date | Ticker | Company | Announcement |
|---|---|---|---|---|
| 17:30 | 11-04-2024 | AZN | AstraZeneca | Result of AGM |
| 07:00 | 11-04-2024 | AZN | AstraZeneca | AstraZeneca increases 2024 dividend by 7% |
| 07:00 | 08-04-2024 | AZN | AstraZeneca | Enhertu approved in US for HER2+ solid tumours |
| 07:00 | 05-04-2024 | AZN | AstraZeneca | Imfinzi improved OS & PFS in limited-stage SCLC |
| 15:00 | 02-04-2024 | AZN | AstraZeneca | Total Voting Rights |
| 07:00 | 02-04-2024 | AZN | AstraZeneca | FDA accepts Dato-DXd BLA for breast cancer |
| 07:05 | 02-04-2024 | AZN | AstraZeneca | Voydeya approved in US |
| 07:00 | 25-03-2024 | AZN | AstraZeneca | Ultomiris approved in the US for NMOSD |
| 07:00 | 19-03-2024 | AZN | AstraZeneca | AstraZeneca to acquire Fusion |
| 07:00 | 14-03-2024 | AZN | AstraZeneca | AstraZeneca to acquire Amolyt |
| 11:00 | 12-03-2024 | AZN | AstraZeneca | Director/PDMR Shareholding |
| 11:00 | 07-03-2024 | AZN | AstraZeneca | Notice of AGM |
| 15:00 | 06-03-2024 | AZN | AstraZeneca | Director/PDMR Shareholding |
| 15:05 | 06-03-2024 | AZN | AstraZeneca | Director/PDMR Shareholding |
| 07:00 | 04-03-2024 | AZN | AstraZeneca | EMA validates Dato-DXd MAAs for NSQ NSCLC and BC |
| 15:00 | 01-03-2024 | AZN | AstraZeneca | Total Voting Rights |
| 07:00 | 26-02-2024 | AZN | AstraZeneca | Voydeya recommended for EU approval |
| 13:15 | 22-02-2024 | AZN | AstraZeneca | Acquisition of Gracell completed |
| 11:00 | 22-02-2024 | AZN | AstraZeneca | Director/PDMR Shareholding |
| 07:00 | 22-02-2024 | AZN | AstraZeneca | AstraZeneca prices a $5bn bond offering |
| 11:00 | 20-02-2024 | AZN | AstraZeneca | Annual Financial Report |
| 15:00 | 19-02-2024 | AZN | AstraZeneca | AstraZeneca completes acquisition of Icosavax |
| 07:00 | 19-02-2024 | AZN | AstraZeneca | Tagrisso improved PFS in Stage III lung cancer |
| 07:05 | 19-02-2024 | AZN | AstraZeneca | FDA accepts Dato-DXd BLA for nonsquamous NSCLC |
| 07:10 | 19-02-2024 | AZN | AstraZeneca | Tagrisso plus chemo approved in US for lung cancer |
| 07:00 | 08-02-2024 | AZN | AstraZeneca | Final Results |
| 15:00 | 01-02-2024 | AZN | AstraZeneca | Total Voting Rights |
| 15:00 | 02-01-2024 | AZN | AstraZeneca | Total Voting Rights |
| 07:00 | 27-12-2023 | AZN | AstraZeneca | AstraZeneca acquires Gracell |
| 07:00 | 22-12-2023 | AZN | AstraZeneca | Wainua (eplontersen) granted first US FDA approval |
| 15:00 | 14-12-2023 | AZN | AstraZeneca | Director/PDMR Shareholding |
| 07:05 | 12-12-2023 | AZN | AstraZeneca | AstraZeneca to acquire Icosavax |
| 15:05 | 01-12-2023 | AZN | AstraZeneca | Block listing Interim Review |
| 15:00 | 01-12-2023 | AZN | AstraZeneca | Total Voting Rights |
| 07:00 | 01-12-2023 | AZN | AstraZeneca | Discontinuation of two CRYSTALIZE evidence trials |
| 15:00 | 23-11-2023 | AZN | AstraZeneca | Director/PDMR Shareholding |
| 07:00 | 17-11-2023 | AZN | AstraZeneca | Truqap approved in US for HR+ breast cancer |
| 07:05 | 14-11-2023 | AZN | AstraZeneca | Update on PACIFIC-2 Phase III trial for Imfinzi |
| 15:00 | 09-11-2023 | AZN | AstraZeneca | Director Declaration |
| 07:00 | 09-11-2023 | AZN | AstraZeneca | 9M and Q3 2023 results |
| 07:10 | 09-11-2023 | AZN | AstraZeneca | Imfinzi combination improves PFS in liver cancer |
| 07:05 | 09-11-2023 | AZN | AstraZeneca | Agreement with Eccogene for clinical stage GLP-1RA |
| 15:00 | 01-11-2023 | AZN | AstraZeneca | Total Voting Rights |
| 07:00 | 01-11-2023 | AZN | AstraZeneca | AstraZeneca cell & gene therapy deal w/ Cellectis |
| 07:00 | 03-10-2023 | AZN | AstraZeneca | AstraZeneca settles Nexium liability litigations |
| 15:00 | 02-10-2023 | AZN | AstraZeneca | Total Voting Rights |
| 07:00 | 22-09-2023 | AZN | AstraZeneca | Dato-DXd improved PFS in breast cancer |
| 07:00 | 20-09-2023 | AZN | AstraZeneca | Alexion completes Pfizer gene therapy agreement |
| 15:00 | 15-09-2023 | AZN | AstraZeneca | Enhertu recommended in EU for HER2-mutant NSCLC |
| 16:00 | 11-09-2023 | AZN | AstraZeneca | Fasenra Phase III EGPA trial met primary endpoint |
| 07:00 | 06-09-2023 | AZN | AstraZeneca | Update on US review of Ultomiris for NMOSD |
| 15:00 | 01-09-2023 | AZN | AstraZeneca | Total Voting Rights |
| 07:05 | 28-07-2023 | AZN | AstraZeneca | Alexion enters gene therapy agreement with Pfizer |
| 07:00 | 28-07-2023 | AZN | AstraZeneca | Half-year Report |
| 15:00 | 03-07-2023 | AZN | AstraZeneca | Total Voting Rights |
| 07:00 | 03-07-2023 | AZN | AstraZeneca | Dato-DXd significantly improved PFS in lung cancer |
| 07:05 | 09-06-2023 | AZN | AstraZeneca | nirsevimab recommended for infant RSV protection |
| 07:00 | 09-06-2023 | AZN | AstraZeneca | AstraZeneca agreement with Quell Therapeutics |
| 17:00 | 02-06-2023 | AZN | AstraZeneca | Imfinzi improved pCR in gastric and GEJ cancers |
| 15:00 | 01-06-2023 | AZN | AstraZeneca | Total Voting Rights |
| 15:05 | 01-06-2023 | AZN | AstraZeneca | Block listing Interim Review |
| 07:00 | 01-06-2023 | AZN | AstraZeneca | Lynparza approved in US for BRCAm prostate cancer |
| 07:00 | 26-05-2023 | AZN | AstraZeneca | Imfinzi + Lynparza prolonged PFS in endometrial ca |
| 07:05 | 22-05-2023 | AZN | AstraZeneca | Directorate Change |
| 07:00 | 17-05-2023 | AZN | AstraZeneca | Tagrisso plus chemo improved PFS in lung cancer |
| 11:00 | 09-05-2023 | AZN | AstraZeneca | Director/PDMR Shareholding |
| 07:00 | 09-05-2023 | AZN | AstraZeneca | Farxiga extended in the US for heart failure |